Ep. 267 - Trump's NIH Pick & Multi-targeted CAR Ts
BioCentury This Week
00:00
Advancements in CAR-T Therapies and Biotech Independence
This chapter explores the progress and challenges in CAR-T therapies, particularly the focus on targeting B cell and plasma cell antigens and the complexities surrounding dual CAR development. It highlights the pivotal role biotech companies play in drug approvals, showcasing their increasing independence and success in bringing innovative treatments to market. Furthermore, the discussion covers the unique hurdles biotechs face, especially in the competitive landscape of autoimmune diseases and the contrast with orphan drug approvals.
Transcript
Play full episode
